Cargando…

The Model for End-Stage Liver Disease (MELD) can predict outcomes in ambulatory patients with advanced heart failure who have been referred for cardiac transplantation evaluation

Risk stratification in heart failure (HF) patients is an important element for management. There are several risk stratification models that can be used to predict the prognosis of patients with HF, such as Aaronson's scale, CVM-HF (CardioVascular Medicine Heart Failure), the Seattle Heart Fail...

Descripción completa

Detalles Bibliográficos
Autores principales: Szyguła-Jurkiewicz, Bożena, Zakliczyński, Michał, Andrejczuk, Mariusz, Mościński, Mateusz, Zembala, Marian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283859/
https://www.ncbi.nlm.nih.gov/pubmed/26336418
http://dx.doi.org/10.5114/kitp.2014.43847
_version_ 1782351326732091392
author Szyguła-Jurkiewicz, Bożena
Zakliczyński, Michał
Andrejczuk, Mariusz
Mościński, Mateusz
Zembala, Marian
author_facet Szyguła-Jurkiewicz, Bożena
Zakliczyński, Michał
Andrejczuk, Mariusz
Mościński, Mateusz
Zembala, Marian
author_sort Szyguła-Jurkiewicz, Bożena
collection PubMed
description Risk stratification in heart failure (HF) patients is an important element for management. There are several risk stratification models that can be used to predict the prognosis of patients with HF, such as Aaronson's scale, CVM-HF (CardioVascular Medicine Heart Failure), the Seattle Heart Failure Model (SHFM) and the Munich score. These models fail to adequately address the impact of multiorgan dysfunction on prognosis. The classical Model for End-Stage Liver Disease (MELD) score consists of: total bilirubin, INR (international normalized ratio) and creatinine level. There are some modifications of the MELD scale: MELD-XI, which excludes the INR score; the mod-MELD score, in which INR is replaced with albumin levels; and MELD-Na, which consists of the bilirubin and creatinine levels, INR ratio and the sodium level. Therefore, the MELD score systems are markers of multisystem dysfunction (renal, cardiac, hepatic). It is important that they are composed of routinely collected laboratory measures which are easy to use.
format Online
Article
Text
id pubmed-4283859
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-42838592015-09-02 The Model for End-Stage Liver Disease (MELD) can predict outcomes in ambulatory patients with advanced heart failure who have been referred for cardiac transplantation evaluation Szyguła-Jurkiewicz, Bożena Zakliczyński, Michał Andrejczuk, Mariusz Mościński, Mateusz Zembala, Marian Kardiochir Torakochirurgia Pol Heart and Lung Failure, Transplantology Risk stratification in heart failure (HF) patients is an important element for management. There are several risk stratification models that can be used to predict the prognosis of patients with HF, such as Aaronson's scale, CVM-HF (CardioVascular Medicine Heart Failure), the Seattle Heart Failure Model (SHFM) and the Munich score. These models fail to adequately address the impact of multiorgan dysfunction on prognosis. The classical Model for End-Stage Liver Disease (MELD) score consists of: total bilirubin, INR (international normalized ratio) and creatinine level. There are some modifications of the MELD scale: MELD-XI, which excludes the INR score; the mod-MELD score, in which INR is replaced with albumin levels; and MELD-Na, which consists of the bilirubin and creatinine levels, INR ratio and the sodium level. Therefore, the MELD score systems are markers of multisystem dysfunction (renal, cardiac, hepatic). It is important that they are composed of routinely collected laboratory measures which are easy to use. Termedia Publishing House 2014-06-29 2014-06 /pmc/articles/PMC4283859/ /pubmed/26336418 http://dx.doi.org/10.5114/kitp.2014.43847 Text en Copyright © 2014 http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License, permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Heart and Lung Failure, Transplantology
Szyguła-Jurkiewicz, Bożena
Zakliczyński, Michał
Andrejczuk, Mariusz
Mościński, Mateusz
Zembala, Marian
The Model for End-Stage Liver Disease (MELD) can predict outcomes in ambulatory patients with advanced heart failure who have been referred for cardiac transplantation evaluation
title The Model for End-Stage Liver Disease (MELD) can predict outcomes in ambulatory patients with advanced heart failure who have been referred for cardiac transplantation evaluation
title_full The Model for End-Stage Liver Disease (MELD) can predict outcomes in ambulatory patients with advanced heart failure who have been referred for cardiac transplantation evaluation
title_fullStr The Model for End-Stage Liver Disease (MELD) can predict outcomes in ambulatory patients with advanced heart failure who have been referred for cardiac transplantation evaluation
title_full_unstemmed The Model for End-Stage Liver Disease (MELD) can predict outcomes in ambulatory patients with advanced heart failure who have been referred for cardiac transplantation evaluation
title_short The Model for End-Stage Liver Disease (MELD) can predict outcomes in ambulatory patients with advanced heart failure who have been referred for cardiac transplantation evaluation
title_sort model for end-stage liver disease (meld) can predict outcomes in ambulatory patients with advanced heart failure who have been referred for cardiac transplantation evaluation
topic Heart and Lung Failure, Transplantology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283859/
https://www.ncbi.nlm.nih.gov/pubmed/26336418
http://dx.doi.org/10.5114/kitp.2014.43847
work_keys_str_mv AT szygułajurkiewiczbozena themodelforendstageliverdiseasemeldcanpredictoutcomesinambulatorypatientswithadvancedheartfailurewhohavebeenreferredforcardiactransplantationevaluation
AT zakliczynskimichał themodelforendstageliverdiseasemeldcanpredictoutcomesinambulatorypatientswithadvancedheartfailurewhohavebeenreferredforcardiactransplantationevaluation
AT andrejczukmariusz themodelforendstageliverdiseasemeldcanpredictoutcomesinambulatorypatientswithadvancedheartfailurewhohavebeenreferredforcardiactransplantationevaluation
AT moscinskimateusz themodelforendstageliverdiseasemeldcanpredictoutcomesinambulatorypatientswithadvancedheartfailurewhohavebeenreferredforcardiactransplantationevaluation
AT zembalamarian themodelforendstageliverdiseasemeldcanpredictoutcomesinambulatorypatientswithadvancedheartfailurewhohavebeenreferredforcardiactransplantationevaluation
AT szygułajurkiewiczbozena modelforendstageliverdiseasemeldcanpredictoutcomesinambulatorypatientswithadvancedheartfailurewhohavebeenreferredforcardiactransplantationevaluation
AT zakliczynskimichał modelforendstageliverdiseasemeldcanpredictoutcomesinambulatorypatientswithadvancedheartfailurewhohavebeenreferredforcardiactransplantationevaluation
AT andrejczukmariusz modelforendstageliverdiseasemeldcanpredictoutcomesinambulatorypatientswithadvancedheartfailurewhohavebeenreferredforcardiactransplantationevaluation
AT moscinskimateusz modelforendstageliverdiseasemeldcanpredictoutcomesinambulatorypatientswithadvancedheartfailurewhohavebeenreferredforcardiactransplantationevaluation
AT zembalamarian modelforendstageliverdiseasemeldcanpredictoutcomesinambulatorypatientswithadvancedheartfailurewhohavebeenreferredforcardiactransplantationevaluation